WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H555878
CAS#: 1228690-36-5 (free acid)
Description: AM095 is a potent LPA1 receptor antagonist because it inhibited GTPγS binding to Chinese hamster ovary (CHO) cell membranes overexpressing recombinant human or mouse LPA1 with IC50 values of 0.98 and 0.73 μM, respectively, and exhibited no LPA1 agonism. Lysophosphatidic acid (LPA) is a bioactive phospholipid that signals through a family of at least six G protein-coupled receptors designated LPA1-6. LPA type 1 receptor (LPA1) exhibits widespread tissue distribution and regulates a variety of physiological and pathological cellular functions.
Hodoodo Cat#: H555878
Name: AM095 free acid
CAS#: 1228690-36-5 (free acid)
Chemical Formula: C27H24N2O5
Exact Mass: 456.17
Molecular Weight: 456.498
Elemental Analysis: C, 71.04; H, 5.30; N, 6.14; O, 17.52
Related CAS #: 1345614-59-6 (sodium) 1228690-36-5 (free acid)
Synonym: AM095 free acid; AM095; AM-095; AM 095;
IUPAC/Chemical Name: 4'-[3-methyl-4-[[[(1R)-1-phenylethoxy]carbonyl]amino]-5-isoxazolyl]-[1,1'-biphenyl]-4-acetic acid
InChi Key: LNDDRUPAICPXIN-GOSISDBHSA-N
InChi Code: InChI=1S/C27H24N2O5/c1-17-25(28-27(32)33-18(2)20-6-4-3-5-7-20)26(34-29-17)23-14-12-22(13-15-23)21-10-8-19(9-11-21)16-24(30)31/h3-15,18H,16H2,1-2H3,(H,28,32)(H,30,31)/t18-/m1/s1
SMILES Code: O=C(O)CC1=CC=C(C2=CC=C(C3=C(NC(O[C@@H](C4=CC=CC=C4)C)=O)C(C)=NO3)C=C2)C=C1
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >3 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 456.50 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Lee JH, Sarker MK, Choi H, Shin D, Kim D, Jun HS. Lysophosphatidic acid receptor 1 inhibitor, AM095, attenuates diabetic nephropathy in mice by downregulation of TLR4/NF-κB signaling and NADPH oxidase. Biochim Biophys Acta Mol Basis Dis. 2019 Jun 1;1865(6):1332-1340. doi: 10.1016/j.bbadis.2019.02.001. Epub 2019 Feb 11. PMID: 30763641.
2: Szepanowski F, Winkelhausen M, Steubing RD, Mausberg AK, Kleinschnitz C, Stettner M. LPA1 signaling drives Schwann cell dedifferentiation in experimental autoimmune neuritis. J Neuroinflammation. 2021 Dec 17;18(1):293. doi: 10.1186/s12974-021-02350-5. PMID: 34920725; PMCID: PMC8680309.
3: Naruse T, Otake H, Takahashi T. Effects of a lysophosphatidic acid receptor 1 antagonist on hypertensive renal injury in Dahl-Iwai salt-sensitive rats. J Pharmacol Sci. 2022 Aug;149(4):179-188. doi: 10.1016/j.jphs.2022.05.003. Epub 2022 May 13. PMID: 35717071.
4: Swaney JS, Chapman C, Correa LD, Stebbins KJ, Broadhead AR, Bain G, Santini AM, Darlington J, King CD, Baccei CS, Lee C, Parr TA, Roppe JR, Seiders TJ, Ziff J, Prasit P, Hutchinson JH, Evans JF, Lorrain DS. Pharmacokinetic and pharmacodynamic characterization of an oral lysophosphatidic acid type 1 receptor-selective antagonist. J Pharmacol Exp Ther. 2011 Mar;336(3):693-700. doi: 10.1124/jpet.110.175901. Epub 2010 Dec 15. PMID: 21159750.
5: Szepanowski F, Szepanowski LP, Mausberg AK, Kleinschnitz C, Kieseier BC, Stettner M. Lysophosphatidic acid propagates post-injury Schwann cell dedifferentiation through LPA1 signaling. Neurosci Lett. 2018 Jan 1;662:136-141. doi: 10.1016/j.neulet.2017.10.023. Epub 2017 Oct 16. PMID: 29051083.
6: Carmona-Rosas G, Alfonzo-Méndez MA, Hernández-Espinosa DA, Romero-Ávila MT, García-Sáinz JA. A549 cells as a model to study endogenous LPA1 receptor signaling and regulation. Eur J Pharmacol. 2017 Nov 15;815:258-265. doi: 10.1016/j.ejphar.2017.09.013. Epub 2017 Sep 21. PMID: 28943105.
7: Im DS. Intercellular Lipid Mediators and GPCR Drug Discovery. Biomol Ther (Seoul). 2013 Nov;21(6):411-22. doi: 10.4062/biomolther.2013.080. PMID: 24404331; PMCID: PMC3879912.
8: Bhattarai S, Sharma S, Subedi U, Ara H, Shum A, Milena M, Bhuiyan MS, Kidambi S, Sun H, Miriyala S, Panchatcharam M. The ATX-LPA Axis Regulates Vascular Permeability during Cerebral Ischemic-Reperfusion. Int J Mol Sci. 2022 Apr 8;23(8):4138. doi: 10.3390/ijms23084138. PMID: 35456953; PMCID: PMC9024554.
9: Gaire BP, Sapkota A, Song MR, Choi JW. Lysophosphatidic acid receptor 1 (LPA1) plays critical roles in microglial activation and brain damage after transient focal cerebral ischemia. J Neuroinflammation. 2019 Aug 20;16(1):170. doi: 10.1186/s12974-019-1555-8. PMID: 31429777; PMCID: PMC6701099.
10: Gento-Caro Á, Vilches-Herrando E, García-Morales V, Portillo F, Rodríguez- Bey G, González-Forero D, Moreno-López B. Interfering with lysophosphatidic acid receptor edg2/lpa1 signalling slows down disease progression in SOD1-G93A transgenic mice. Neuropathol Appl Neurobiol. 2021 Dec;47(7):1004-1018. doi: 10.1111/nan.12699. Epub 2021 Feb 10. PMID: 33508894.
11: Lee GH, Cheon J, Kim D, Jun HS. Lysophosphatidic Acid Promotes Epithelial- Mesenchymal Transition in Kidney Epithelial Cells via the LPAR1/MAPK-AKT/KLF5 Signaling Pathway in Diabetic Nephropathy. Int J Mol Sci. 2022 Sep 10;23(18):10497. doi: 10.3390/ijms231810497. PMID: 36142408; PMCID: PMC9500642.
12: Castelino FV, Seiders J, Bain G, Brooks SF, King CD, Swaney JS, Lorrain DS, Chun J, Luster AD, Tager AM. Amelioration of dermal fibrosis by genetic deletion or pharmacologic antagonism of lysophosphatidic acid receptor 1 in a mouse model of scleroderma. Arthritis Rheum. 2011 May;63(5):1405-15. doi: 10.1002/art.30262. PMID: 21305523; PMCID: PMC3086986.
13: Srikanth M, Chew WS, Hind T, Lim SM, Hay NWJ, Lee JHM, Rivera R, Chun J, Ong WY, Herr DR. Lysophosphatidic acid and its receptor LPA1 mediate carrageenan induced inflammatory pain in mice. Eur J Pharmacol. 2018 Dec 15;841:49-56. doi: 10.1016/j.ejphar.2018.10.005. Epub 2018 Oct 12. PMID: 30321532.
14: Yonezu Y, Tanabe S, Misawa H, Muramatsu R. Lysophosphatidic acid stimulates pericyte migration via LPA receptor 1. Biochem Biophys Res Commun. 2022 Aug 27;618:61-66. doi: 10.1016/j.bbrc.2022.06.016. Epub 2022 Jun 8. PMID: 35716596.
15: Aikawa S, Kano K, Inoue A, Aoki J. Proliferation of mouse endometrial stromal cells in culture is highly sensitive to lysophosphatidic acid signaling. Biochem Biophys Res Commun. 2017 Feb 26;484(1):202-208. doi: 10.1016/j.bbrc.2016.12.154. Epub 2017 Jan 7. PMID: 28073697.
16: Velasco M, O'Sullivan C, Sheridan GK. Lysophosphatidic acid receptors (LPARs): Potential targets for the treatment of neuropathic pain. Neuropharmacology. 2017 Feb;113(Pt B):608-617. doi: 10.1016/j.neuropharm.2016.04.002. Epub 2016 Apr 5. PMID: 27059127.
17: Fernandes MF, Tomczewski MV, Duncan RE. Glucagon-like Peptide-1 Secretion Is Inhibited by Lysophosphatidic Acid. Int J Mol Sci. 2022 Apr 9;23(8):4163. doi: 10.3390/ijms23084163. PMID: 35456981; PMCID: PMC9025735.
18: Forte N, Fernández-Rilo AC, Palomba L, Marfella B, Piscitelli F, De Girolamo P, Di Costanzo A, Di Marzo V, Cristino L. Positive association between plasmatic levels of orexin A and the endocannabinoid-derived 2-arachidonoyl lysophosphatidic acid in Alzheimer's disease. Front Aging Neurosci. 2022 Nov 16;14:1004002. doi: 10.3389/fnagi.2022.1004002. PMID: 36466600; PMCID: PMC9710385.
19: Prakash E, Pavithra S, Kishor Kumar DG, Panigrahi M, Singh TU, Kumar D, Parida S. TXA2 mediates LPA1-stimulated uterine contraction in late pregnant mouse. Prostaglandins Other Lipid Mediat. 2023 Aug;167:106736. doi: 10.1016/j.prostaglandins.2023.106736. Epub 2023 Apr 14. PMID: 37062326.
20: Ninou I, Kaffe E, Müller S, Budd DC, Stevenson CS, Ullmer C, Aidinis V. Pharmacologic targeting of the ATX/LPA axis attenuates bleomycin-induced pulmonary fibrosis. Pulm Pharmacol Ther. 2018 Oct;52:32-40. doi: 10.1016/j.pupt.2018.08.003. Epub 2018 Sep 7. PMID: 30201409.
